European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 5, 2020

Alkaline Phosphatase And Its Clinical Importance-A Review

Dr. R.Jayasri Krupaa, Dr.R.Hariharan, Dr.N.Aravindha Babu, Dr. K.M.K.Masthan

, Department of Oral pathology and Microbiology
Sree Balaji Dental College and Hospital
Bharath Institute of Higher Education and Research

ABSTRACT:

Serum alkaline phosphatase (ALP) is an individual from a group of zinc metalloprotein enzymes that works to separate a terminal phosphate group from aorganic phosphate ester. Numerous things may cause increments of ALP activity in serum, themost common being obstructive liver disease and metabolic bone disease. An increase of the liver or especially the bone isoform (bone specific ALP) in serum can give important diagnostic data. Bone specific alkaline phosphatase isoenzyme is raised because of increased osteoblastic activity. The most elevated absolute ALP values have been credited to an expanded bone isoenzymelevel because of Paget disease or rickets/osteomalacia. The compound action, which is restricted in the plasma membrane of osteoblasts prior to extracellular delivery, associates with the degree of the infection on skeletal studies and with boundaries of bone resorption. This isoenzymes is regularly raised in developing youngsters and grown-ups over the age of fifty. Reasons for high bone ALP includes bone development, healing fracture, acromegaly, osteogenic sarcoma, or bone metastases, leukemia, myelofibrosis, and once in a while myeloma; soALP is utilized as a tumor marker.Hyperthyroidism, by its impact upon bone, may likewise raise ALP. This article reviews the characteristics, diagnostics and clinical significance of ALP.

KEY WORDS: *Alkaline phosphatases, bone diseases, isoenzymes,Paget disease, osteomalacia.*

INTRODUCTION:

Alkaline phosphatases are a group of isoenzymes, situated on the external layer of the cell membrane; they catalyze the hydrolysis of organic phosphate esters present in the extracellular space. Zinc and magnesium are significant co-factor of this enzyme. Thoughalkaline phosphatases are available in various body tissues and have distinctive physiochemical properties, these are true isoenzyme that they catalyze a similar reaction. In the liver, alkaline phosphatase is cytosolic and present in the canalicular membrane of the hepatocyte. Alkaline phosphatase is available in decreasing levels in placenta, ileal mucosa, kidney, bone and liver.However most of the alkaline phosphatase in serum (over 80%) is delivered from liver and bone, and in modest quantities from the intestines. Despite the fact that alkaline phosphatases are found in numerous tissues all through the body, their exact physiological capacity remains to a great extent unknown.[1,2] Alkaline phosphatases are named tissue-specific and tissue non specifictypes. Alkaline phosphatases found in the intestine, placenta, and germinal tissue will be tissue-specific, which implies they are discovered distinctly in the tissues where they are appeared in physiological conditions.Howeverthey may add to the coursing pool of serum alkaline phosphatase under specific circumstances when there is increased stimulation of their synthesis. The tissue-non specificalkaline phosphatase frames most of the portion circling in serum and thusly, is of clinical interest. It is encoded by a single gene and is expressed in the liver, bone, and kidneys. Intestinal alkaline phosphatase is coded by a different gene, which is unique in relation to the gene that codes for placental alkaline phosphatase and the Regan isoenzyme (which is created in overabundance amounts in Hodgkin lymphoma). All tissue-non specific AP have a similar amino acidsequence yet extraordinary glucose and lipid side chains; post-translational alterations give their special physicochemical properties.[3,4]

ETIOLOGY AND EPIDEMIOLOGY:

Serum alkaline phosphatase levels will varies with age in ordinary people. Levels are high during adolescence and puberty because of bone development and bone growth. The decline in level in the 15 to 50 year age group is marginally higher in male than in female. These levels rise again in old age (critical distinction among genders). The explanations behind these typical varieties are not known. Various studieshas indicated a positive relationship with body weight and smoking, and there is an opposite connection with height.[5,6,7] In normal people, the circulating enzyme is fundamentally gotten from liver and bone. In certain people, this enzyme comes from the intestinal tract to an insignificant degree. In people with blood groups O and B, serum alkaline phosphatase levels increment subsequent to devouring a fatty meal, because of commitment from the intestinal tract. As this increment can continue for as long as 12 hours in the serum, the suggestion is to check the serum enzyme levels in a fasting state.[8]

PATHOPHYSIOLOGY:

Alkaline phosphatase acts like some other serum protein. It has a half-life of 7 days, and clearance from serum is autonomous of bile duct patency or functional ability of the liver. Notwithstanding, the site of destruction of alkaline phosphatase isn't known. Serum alkaline phosphatase levels may stay raised for upto 1 week after the treatment of biliary obstruction. The liver is the source in many patients with raised enzyme levels. Expanded osteoblast action found in the bone disorders or typically during phase of growth is the following likely donor. The convergence of placental alkaline phosphatase in the late third trimester adds to the ascent in pregnant women.[9] The mechanism of the increments in alkaline phosphatase in hepatobiliary disorders has involved discussion. Studies have convincingly indicated that it is because of increased enzymeproduction and not to decreased hepatobiliary excretion of the enzyme. Raised hepatic enzyme action verifiably matches the ascent in serum alkaline phosphatase activity; this happens principally because of increased translation of the mRNA of alkaline phosphatase (interceded by the increasing bile acidconcentration) and increased emission of alkaline phosphatase into serum through canalicular spillage into the hepatic sinusoid. The process that hastens its delivery into the circulation has not been explained. Studies report that vesicles containing alkaline phosphatase, and numerous such enzymes bound to the sinusoidal membranes, are found in the serum of patients with cholestasis. Since alkaline phosphatase is recently produced in response of biliary obstruction, its serum level might be ordinary in the beginning stage of acute biliary obstructioneven when the serum aminotransferases are at their peak. [9,10]

DIAGNOSTICS TESTS:

There are a few clinical techniques for the interpretation of serum alkaline phosphatase levels. They contrast by substrate utilized, pH of the alkalinebuffer, and the "normal" values created. The tests, done with constant principle, depend on the capacity of the enzyme to hydrolyze phosphate esters. In the most generally utilized worldwide strategy, p-nitrophenol phosphate fills in as the substrate, while an amino alcohol is utilized as a buffer. The pace of release of p-nitrophenol phosphate from the substrate is quantifiable as a marker of alkaline phosphatase action and results are accounted for in international units per liter (IU/L). The various techniques show up similarly effective in the identification of abnormal values in different clinical infections. The upper limit of normal values and their multiples are useful in comparing results derived via different tests. [11,12] Electrophoresis doesn't dependably separate the isoenzymes as the electrophoretic mobility of bone and liver isoenzymes is just somewhat variable. Electrophoresis on cellulose acetate, with the expansion of heat inactivation, is a much dependable test than electrophoresis alone. Polyacrylamide gel section based detachment gives precise identification of the liver, bone, intestinal and placental isoenzymes; this test is, in any case, not broadly accessible. [13]

TESTING PROCEDURES:

Patients with blood group O and B may have to quick before the test to evade commitment from the intestinal isoenzyme if there is an unexplained elevation of alkaline phosphatase on routine tests. The phlebotomist utilizes a gold-top serum separator tube containing a clot activator and serum gel separator to gather the blood for examination.

INTERFERING FACTORS:

There are numerous sources of errors which occurring during estimation of ALP. Factors, for example, convergences of phosphate, magnesium, citrate, type and concentration of buffer maintenance of the appropriate temperature may influence the outcome.

RESULTS:

At the point when alkaline phosphatase is the main liver bioenzyme test that presents as raised (i.e., when the serum aminotransferases are under normal value), or when alkaline phosphatase is excessively raised contrasted with other liver biochemical tests, assessment of the patient should concentrate on distinguishing the reason and the origin for the isolated alkaline phosphatase elevation. In asymptomatic patients with isolatedincrease of serum alkaline phosphatase, it is important to recognize the essential source of variation from the normal. Alkaline phosphatases got from the liver, bone, placenta, and intestines have distinctive physicochemical properties. There are three general strategies that have demonstrated to be especially utilized for separating between isoenzymes: thermostability studies; differential restraint with numerous small peptides, amino acids, and other low molecular weight substances; and immunologic methods.[14] One methodology uses the estimation of the action of those enzymes, which increment in concordance with the liver alkaline phosphatase, for example, 5'- nucleotidase (5NT) and gamma-glutamyl transpeptidase (GGT). These enzymes are not raised in bone disorders and associate well with hepatobiliary messes. Serum GGT is extremely sensitive to biliary tract illness yet is less specific for liver disorders. 5NT levels may get raised in pregnant patients; in any case, in non-pregnant patients, it is moderately specific for liver disorder and connects firmly with serum alkaline phosphatase of liver origin. In any case, absence of a raised 5NT within the sight of a raised alkaline phosphatase doesn't exclude hepatobiliary sickness as they don't rise correspondingly in right on time or gentle hepatic injury.[15]

CLINICAL SIGNIFICANCE:

The principal clinical value of estimating serum alkaline phosphatase lies in the diagnosis of cholestatic liver illness—in some cases, rises in alkaline phosphatases present in patients with cholestasis. Typically, four times of the upper limits or higher increment happens in up to 75% of the patients with cholestasis, either intrahepatic or extrahepatic. The level of elevation doesn't help recognize the two types. Comparable rises happen in biliary obstruction because of malignant growth (cholangiocarcinoma, pancreatic head adenocarcinoma, or ampullary adenocarcinoma), choledocholithiasis, biliary injury, sclerosing cholangitis, or reasons for intrahepatic cholestasis, for example, primary biliary cholangitis, drug-initiated liver injury, constant dismissal of liver allografts, infiltrative liver infection (sarcoidosis, amyloidosis, tuberculosis, and liver metastasis), severe alcoholic hepatitis causing steatonecrosis. Patients with AIDS may likewise have especially elevated levels, either due to cholangiopathy from opportunistic infections, for example, cytomegalovirus, cryptosporidiosis, or granulomatous contribution of the liver from tuberculosis.[16,17] Moderate increase (up to multiple times the upper limit of normal) of serum alkaline phosphatase is vague as it can happen in various conditions influencing the liver including cirrhosis, persistent hepatitis, viral hepatitis, congestive cardiovascular failure, and ischemic cholangiopathy. Problems that don't initially include the liver, for example, intra-abdominal diseases, cholestasis of sepsis, Hodgkin lymphoma, myeloid metaplasia, and osteomyelitis can likewise cause moderate rise of serum alkaline phosphatase. Primary or metastatic cancer raises serum alkaline phosphatase levels by nearby bile duct obstruction and expanding spillage of the liver isoenzyme. Primary extrahepatic malignancy doesn't really need to include the liver or the bone; infrequently, a few tumors can deliver their own alkaline phosphatase (Hodgkin lymphoma emitting the Regan isoenzyme) or apply a paraneoplastic impact causing spillage of the hepatic isoenzyme into the dissemination (Stauffer syndrome because of renal cell carcinoma).[18,19] Unusually low levels can be valuable clinically as they are found in Wilson's disease, particularly while introducing in a fulminant form with hemolysis. Zinc is a cofactor of Alkaline phosphatase, which gets dislodged by copper in Wilson's sickness, a problem of copper over-burden, subsequently prompting low levels. Different reasons for low alkaline phosphatase levels are zinc insufficiency, pernicious anemia, hypothyroidism, and congenital hypophosphatasia.[20] A broad assessment is frequently not required in those patients who have just a gentle rise of serum alkaline phosphatase (under half rise). Such patients might be noticed clinically with intermittent observing of serum liver biochemical tests. At whatever point alkaline phosphatase levels are unusually raised, further assessment

should happen to decide if the source is hepatic or non-hepatic. A hepatic source for a raised alkaline phosphatase level is upheld by the corresponding height of either GGT or 5NT. On the off chance that the source is non-hepatic, at that point the assessment of the other disorder is the following stage. A raised bone alkaline phosphatase can happen in bone metastasis, Paget disease, osteogenic sarcoma, fractures healing, hyperparathyroidism, hyperthyroidism, and osteomalacia. Raised intestinal fraction level occur after a fatty meal and runs in families; this doesn't need extra assessment. In cases of liver as a suspected source, imaging of the biliary tree is important to separate between extrahepatic or intrahepatic cholestasis notwithstanding exploring the drug list.[15,21,22] A right upper quadrant ultrasonography is regularly the principal imaging study requested. If the bile duct has become enlarged, either endoscopic retrograde cholangiopancreatography (ERCP) or attractive reverberation cholangiopancreatography (MRCP) is finished relying upon the clinical sign. In the event, that the bile channel doesn't show enlargement, testing for serum antimitochondrial antibody (AMA) is the recommended following stage to assess for essential biliary cholangitis (PBC). In the event that serum AMA is typical, assessment for reasons for intrahepatic cholestasis, AMA-negative PBC, sarcoidosis, and different other previously described disorders are important. Liver biopsy is frequently the last test utilized in such circumstances as it assists with recognizing the etiology of raised serum alkalinephosphatase.[23,24]

CONCLUSION:

Analkaline phosphatase test might be requested by a medical professionals as a component of a standard examination or if the patient has symptoms of a bone disorder or liver damage. Proper assessment and characterization, by the patient's medical care group, of any anomalous alkaline phosphatase levels and related findings bring about better medical care results for the patient and thereby determining the absolute treatment plan of the patient.

REFERENCES:

1. Pinart M, Kunath F, Lieb V, Tsaur I, Wullich B, Schmidt S., German Prostate Cancer Consortium (DPKK) Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World J Urol. 2020 Mar;38(3):613-635. [Abstract]

2.van der Doelen MJ, Mehra N, Hermsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clin Genitourin Cancer. 2019 Apr;17(2):79-87. [Abstract]

3.Castells L, Cassanello P, Muñiz F, de Castro MJ, Couce ML. Neonatal lethal hypophosphatasia: A case report and review of literature. Medicine (Baltimore) 2018 Nov;97(48):e13269. [Abstract]

4.Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M. Prognostic models in primary biliary cholangitis. J Autoimmun. 2018 Dec;95:171-178. [Abstract]

5.Azpiazu D, Gonzalo S, Villa-Bellosta R. Tissue Non-Specific Alkaline Phosphatase and Vascular Calcification: A Potential Therapeutic Target. CurrCardiol Rev. 2019;15(2):91-95. [Abstract]

6.Brichacek AL, Brown CM. Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metab Brain Dis. 2019 Feb;34(1):3-19. [Abstract]

7.Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol. 2018 Oct;14(24):2543-2556. [Abstract]

8.Matsushita M, Harajiri S, Tabata S, Yukimasa N, Muramoto Y, Komoda T. [Alkaline phosphatase activity in blood group B or O secretors is fluctuated by the dinner intake of previous night]. RinshoByori. 2013 Apr;61(4):307-12. [Abstract]

9.Masrour Roudsari J, Mahjoub S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget's specimens. Caspian J Intern Med. 2012 Summer;3(3):478-83. [Abstract]

10. Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R. A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. BiochimBiophys Acta. 2013 Dec;1832(12):2044-56. [Abstract]

11. Sancenon V, Goh WH, Sundaram A, Er KS, Johal N, Mukhina S, Carr G, Dhakshinamoorthy S. Development, validation and quantitative assessment of an enzymatic assay suitable for small molecule screening and profiling: A case-study. Biomol Detect Quantif. 2015 Jun;4:1-9. [Abstract]

12. Tietz NW, Burtis CA, Duncan P, Ervin K, Petitclerc CJ, Rinker AD, Shuey D, Zygowicz ER. A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem. 1983 May;29(5):751-61. [Abstract]

13. Siede WH, Seiffert UB. Quantitative alkaline phosphatase isoenzyme determination by electrophoresis on cellulose acetate membranes. Clin Chem. 1977 Jan;23(1):28-34. [Abstract]

14. Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014 Jul;29(3):269-78. [Abstract]

15. Vroon DH, Israili Z. Alkaline Phosphatase and Gamma Glutamyltransferase. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd. Butterworths; Boston: 1990. [Abstract]

16. Shamban L, Patel B, Williams M. Significantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure. Gastroenterology Res. 2014 Apr;7(2):64-68. [Abstract]

17. Gao Y, Chin K, Mishriki YY. AIDS Cholangiopathy in an Asymptomatic, Previously Undiagnosed Late-Stage HIV-Positive Patient from Kenya. Int J Hepatol. 2011;2011:465895. [Abstract]

18. Bukowczan J, Pattman S, Jenkinson F, Quinton R. Regan isoenzyme of alkaline phosphatase as a tumour marker for renal cell carcinoma. Ann Clin Biochem. 2014 Sep;51(Pt 5):611-4. [Abstract]

19. Kranidiotis GP, Voidonikola PT, Dimopoulos MK, Anastasiou-Nana MI. Stauffer's syndrome as a prominent manifestation of renal cancer: a case report. Cases J. 2009 Jan 13;2(1):49. [Abstract]

20. Shaver WA, Bhatt H, Combes B. Low serum alkaline phosphatase activity in Wilson's disease. Hepatology. 1986 Sep-Oct;6(5):859-63. [Abstract]

21. Verma J, Gorard DA. Persistently elevated alkaline phosphatase. BMJ Case Rep. 2012 Aug 24;2012 [Abstract]

22. Assy N, Jacob G, Spira G, Edoute Y. Diagnostic approach to patients with cholestatic jaundice. World J Gastroenterol. 1999 Jun;5(3):252-262. [Abstract]

23. Revzin MV, Scoutt LM, Garner JG, Moore CL. Right Upper Quadrant Pain: Ultrasound First! J Ultrasound Med. 2017 Oct;36(10):1975-1985. [Abstract]

24. Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis. 2012 May;16(2):199-229. [Abstract]